Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ATAI

ATAI - ATA Inc-China Stock Price, Fair Value and News

1.85USD-0.03 (-1.60%)Delayed as of 22 Feb 2024, 03:02 pm ET
Watchlist

Market Summary

USD1.85-0.03
Delayedas of 22 Feb 2024, 03:02 pm
-1.60%

ATAI Stock Price

View Fullscreen

ATAI RSI Chart

ATAI Valuation

Market Cap

312.1M

Price/Earnings (Trailing)

-4.66

Price/Sales (Trailing)

934.43

EV/EBITDA

-4.35

Price/Free Cashflow

-3.35

ATAI Price/Sales (Trailing)

ATAI Profitability

EBT Margin

-18050.30%

Return on Equity

-25.14%

Return on Assets

-21.72%

Free Cashflow Yield

-29.82%

ATAI Fundamentals

ATAI Revenue

Revenue (TTM)

334.0K

Rev. Growth (Yr)

262.5%

Rev. Growth (Qtr)

-49.42%

ATAI Earnings

Earnings (TTM)

-66.9M

Earnings Growth (Yr)

230.56%

Earnings Growth (Qtr)

233.9%

Breaking Down ATAI Revenue

52 Week Range

1.142.39
(Low)(High)

Last 7 days

6.4%

Last 30 days

-6.1%

Last 90 days

65.8%

Trailing 12 Months

5.1%

How does ATAI drawdown profile look like?

ATAI Financial Health

Current Ratio

10.96

Debt/Equity

0.06

Debt/Cashflow

-6.2

ATAI Investor Care

Shares Dilution (1Y)

0.08%

Diluted EPS (TTM)

-0.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023252.0K271.0K334.0K0
202215.3M10.3M5.3M233.0K
202100020.4M

Tracking the Latest Insider Buys and Sells of ATA Inc-China

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 16, 2023
brand florian
bought
23,120
1.156
20,000
see remarks
Sep 13, 2023
brand florian
bought
57,968
1.4492
40,000
see remarks
Mar 29, 2023
brand florian
bought
103,558
1.4794
70,000
see remarks
Mar 29, 2023
apeiron investment group ltd.
bought
1,600,440
1.318
1,214,300
-
Apr 29, 2022
apeiron investment group ltd.
bought
97,801
4.4658
21,900
-
Apr 28, 2022
apeiron investment group ltd.
bought
154,689
4.4579
34,700
-
Apr 27, 2022
apeiron investment group ltd.
bought
91,939
4.6427
19,803
-
Apr 26, 2022
apeiron investment group ltd.
bought
216,628
4.6882
46,207
-
Apr 25, 2022
apeiron investment group ltd.
bought
42,842
4.781
8,961
-
Apr 22, 2022
apeiron investment group ltd.
bought
254,962
4.827
52,820
-

1–10 of 28

Which funds bought or sold ATAI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Virtus ETF Advisers LLC
sold off
-100
-71,665
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
710
198,048
223,231
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-8.53
-
346,000
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-71.88
-54,014
23,850
-%
Feb 15, 2024
Gould Capital, LLC
added
100
3,950
7,050
-%
Feb 15, 2024
MONETA GROUP INVESTMENT ADVISORS LLC
added
11.83
3,656
20,098
-%
Feb 14, 2024
Tudor Investment Corp Et Al
sold off
-100
-45,150
-
-%
Feb 14, 2024
UBS ASSET MANAGEMENT AMERICAS INC
sold off
-100
-93,499
-
-%
Feb 14, 2024
D. E. Shaw & Co., Inc.
new
-
152,517
152,517
-%
Feb 14, 2024
JANUS HENDERSON GROUP PLC
sold off
-100
-78,891
-
-%

1–10 of 45

Are Funds Buying or Selling ATAI?

Are funds buying ATAI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ATAI
No. of Funds

Unveiling ATA Inc-China's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
apeiron investment group ltd.
20.1%
33,885,999
SC 13G/A
Feb 10, 2023
apeiron investment group ltd.
19.4%
32,671,702
SC 13G/A
Mar 01, 2022
galaxy group funding eci u llc
6.7%
10,796,736
SC 13G
Feb 10, 2022
apeiron investment group ltd.
19.7%
32,059,504
SC 13G

Recent SEC filings of ATA Inc-China

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 06, 2024
8-K
Current Report
Jan 23, 2024
8-K
Current Report
Jan 09, 2024
8-K
Current Report
Jan 09, 2024
4
Insider Trading
Jan 04, 2024
8-K
Current Report
Jan 04, 2024
8-K
Current Report
Nov 20, 2023
4
Insider Trading
Nov 14, 2023
8-K
Current Report
Nov 14, 2023
10-Q
Quarterly Report

Peers (Alternatives to ATA Inc-China)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.4B
9.1B
-16.59% -47.80%
-9.64
3.66
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
19.5B
1.8B
-23.99% -31.71%
-44.27
10.66
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.44
7.22
15.05% 75.21%
13.5B
3.7B
-7.62% -26.87%
22.67
3.67
8.87% 75.42%
MID-CAP
7.9B
272.9M
-2.06% 34.31%
-13.08
29.05
141.38% 4.43%
5.9B
107.9M
-3.85% 226.12%
-9.53
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.44
6.46
23.54% 31.53%
3.9B
223.4M
8.92% 47.81%
-19.25
17.39
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.18
15.02
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.56
4.2
81.69% -7.29%
472.8M
1.0B
-9.17% -57.89%
-0.86
0.45
-43.15% 58.48%
179.5M
4.9M
-14.18% -58.18%
-1.09
36.72
-57.57% 50.48%
120.1M
881.7K
289.54% 381.25%
-2.53
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

ATA Inc-China News

Latest updates
Yahoo Canada Finance2 years ago

ATA Inc-China Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Revenue-49.4%87,000172,00037,00038,00024,00092,667161,333230,000266,000-19,880,000
Operating Expenses-16.0%26,921,00032,034,00033,251,00037,603,50038,447,00035,527,00033,442,00045,405,00033,627,00061,319,00015,830,000
  S&GA Expenses-17.7%13,631,00016,558,00013,970,00015,727,50019,419,00017,221,00017,982,00025,877,00020,264,00037,331,0009,273,000
EBITDA Margin65.5%-172-499-536-577-27.39-13.36-11.35-6.70---
Interest Expenses4.3%686,000658,000622,000508,000-------
Income Taxes28.6%238,000185,000165,0006,015,500135,00051,00041,0003,557,000400,00058,0006,000
Earnings Before Taxes238.5%43,847,000-31,658,000-33,156,000-39,321,000-33,134,000-30,806,000-31,921,000-48,579,000-26,474,000-67,301,0005,753,000
EBT Margin64.4%-180-506-541-580-27.41-13.37-11.36-6.70---
Net Income233.9%44,244,000-33,042,000-33,135,000-45,011,000-33,887,000-36,618,000-36,869,000-88,877,000-31,158,000-48,461,000688,000
Net Income Margin62.6%-200-535-589-654-37.25-18.78-13.39-8.24---
Free Cashflow18.4%-18,431,000-22,585,000-21,391,000-30,647,000-28,504,000-22,047,000-24,042,000-20,561,000-27,933,0001,774,000-16,699,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets21.5%308254281305343349384414484506309112
  Current Assets-11.1%216243268287317324349375442458-100
    Cash Equivalents-45.8%77.0014118619114384.0012436243045410497.00
  Net PPE-4.9%1.001.001.001.001.000.000.000.000.000.00-0.00
Liabilities4.6%40.0038.0040.0040.0047.0029.0029.0028.0021.0021.0019.0016.00
  Current Liabilities9.9%20.0018.0020.0020.0026.0022.0022.0021.0015.0014.00-12.00
  Long Term Debt0.6%15.0015.0015.0015.0015.00-------
Shareholder's Equity25.3%266213237261289312346377453475-91.00
  Retained Earnings7.7%-532-576-543-510-465-431-394-357-268-237--189
  Additional Paid-In Capital1.0%799792783774762746735725709691-262
Shares Outstanding0%166166166166155154154161134132119115
Minority Interest-27.6%2.003.004.005.007.008.008.009.0010.0010.009.005.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations18.5%-18.43-22.61-21.11-30.50-28.04-21.93-23.99-20.51-28.112.00-16.52---
  Share Based Compensation-5.8%8.009.009.0012.0011.0010.0010.0013.0012.0038.000.00---
Cashflow From Investing-111.2%-46.48-22.0016.0080.0066.00-18.21-214-48.63-0.61-28.31-3.72---
Cashflow From Financing100.0%--0.100.00-0.9220.002.000.002.004.0037430.00---

ATAI Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
License revenue$ 87$ 24$ 296$ 195
Operating expenses:    
Research and development13,29019,02848,04752,437
Acquisition of In Process Research and Development000357
General and administrative13,63119,41944,15954,623
Total operating expenses26,92138,44792,206107,417
Loss from operations(26,834)(38,423)(91,910)(107,222)
Other income (expense), net:    
Interest income6121451,191361
Interest expense(686)0(1,965)0
Change in fair value of contingent consideration liability - related parties(58)43053525
Change in Fair Value of Warrant Liability00053
Change in fair value of securities carried at fair value1,8323443,322(981)
Change in fair value of other investments held at fair value69,014069,0140
Change in fair value of convertible notes receivable - related party220220
Foreign exchange gain (loss), net2534,470(593)11,515
Other income (expense), net(308)(100)(100)(112)
Total other income (expense), net70,6815,28970,94411,361
Net income (loss) before income taxes43,847(33,134)(20,966)(95,861)
Provision for income taxes(238)(135)(588)(227)
Losses from investments in equity method investees, net of tax(238)(2,432)(3,199)(14,680)
Net income (loss)43,371(35,701)(24,753)(110,768)
Net income (loss) attributable to noncontrolling interests(873)(1,814)(2,821)(3,394)
Net income (loss) attributable to ATAI Life Sciences N.V. stockholders$ 44,244$ (33,887)$ (21,932)$ (107,374)
Net income (loss) per share attributable to ATAI Life Sciences N.V. shareholders - basic$ 0.28$ (0.22)$ (0.14)$ (0.69)
Net income (loss) per share attributable to ATAI Life Sciences N.V. stockholders - diluted$ 0.25$ (0.22)$ (0.14)$ (0.69)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - basic (denominator)155,792,490156,607,468155,793,601154,713,922
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - diluted177,565,973156,607,468155,793,601154,713,922

ATAI Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 76,492$ 190,613
Securities carried at fair value132,50282,496
Prepaid expenses and other current assets6,83114,036
Total current assets215,825287,145
Property and equipment, net992928
Operating lease right-of-use asset, net1,258226
Other Investments held at fair value71,5110
Other investments3,6596,755
Convertible notes receivable - related party1,5190
Long term notes receivable - related parties, net10,3497,262
Other assets3,1073,125
Total assets308,220305,441
Current liabilities:  
Accounts payable5,5062,399
Accrued liabilities13,00817,306
Current portion of lease liability292180
Other current liabilities88912
Total current liabilities19,69519,897
Contingent consideration liability - related parties900953
Non-current portion of lease liability1,01144
Convertible promissory notes - related parties, net of discounts and deferred issuance costs410415
Long-term debt, net14,95614,702
Other liabilities2,7363,664
Total liabilities39,70839,675
Commitments and contingencies (Note 16)
Stockholders' equity:  
Common stock, 0.10 par value ($0.12 par value at September 30, 2023 and December 31, 2022, respectively); 750,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 166,010,476 and 165,935,914 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively18,57118,562
Additional paid-in capital799,461774,092
Share subscription receivable0(24)
Accumulated other comprehensive loss(19,109)(21,702)
Accumulated deficit(532,647)(510,188)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders266,276260,740
Noncontrolling interests2,2365,026
Total stockholders' equity268,512265,766
Total liabilities and stockholders' equity$ 308,220$ 305,441
ATAI
ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.
 CEO
 WEBSITEwww.atai.life
 EMPLOYEES133

ATA Inc-China Frequently Asked Questions


What is the ticker symbol for ATA Inc-China? What does ATAI stand for in stocks?

ATAI is the stock ticker symbol of ATA Inc-China. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ATA Inc-China (ATAI)?

As of Wed Feb 21 2024, market cap of ATA Inc-China is 312.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers.

What is the fair value of ATAI stock?

You can check ATAI's fair value in chart for subscribers. The fair value of ATA Inc-China is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ATA Inc-China is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ATA Inc-China a good stock to buy?

The fair value guage provides a quick view whether ATAI is over valued or under valued. Whether ATA Inc-China is cheap or expensive depends on the assumptions which impact ATA Inc-China's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATAI.

What is ATA Inc-China's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, ATAI's PE ratio (Price to Earnings) is -4.66 and Price to Sales (PS) ratio is 934.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATAI PE ratio will change depending on the future growth rate expectations of investors.